M. Desrois et al., L-arginine during long-term ischemia: Effects on cardiac function, energetic metabolism and endothelial damage, J HEART LUN, 19(4), 2000, pp. 367-376
Background: We have evaluated the addition of L-arginine, a precursor of ni
tric oxide, to a cardioplegic solution (named CRMBM) designed for long-term
heart preservation.
Methods: Isolated isovolumic-perfused rat hearts (n = 22) were arrested wit
h the CRMBM solution either with (Arg) or without L-arginine (2 mmol/L) (Ar
g group, n = 12, vs control group n = 10), submitted to 8 hours of cold sto
rage (4 degrees C) in the solution, and then reperfused for 60 minutes at 3
7 degrees C. In 11 hearts, we evaluated the quality of cardiac preservation
with P-31 magnetic resonance spectroscopy and the measure of function and
cellular integrity. Endothelium-dependent and independent vasodilatations w
ere measured in 11 other hearts, using 5-hydroxytryptamine and papaverine t
o assess endothelial and smooth muscle function.
Results: Adding L-arginine to the cardioplegic solution improved functional
recovery during reflow, as shown by the rate pressure product (31% +/- 3%
for control vs 47% +/- 3% for Arg, p = 0.003) together with higher coronary
flow and diminished contracture. Purine release in coronary effluents duri
ng reperfusion was lower in the Arg group. During ischemia and reflow kinet
ics of intracellular pH and high-energy phosphates were similar ill both gr
oups. Coronary endothelium-dependent vasodilatation was similarly impaired
in both groups, but smooth muscle was less altered with L-arginine.
Conclusion: As an additive to the CRMBM cardioplegic solution, L-arginine p
rovides a protective effect for long-term heart preservation. Our data do n
ot show coronary endothelial protection as the prominent mechanism.